Julia Lohman

Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase

Brian K. Albrecht, Jean-Christophe Harmange, David Bauer et al. · Journal of Medicinal Chemistry · 2008 · 139 citations · Full text

Medicine, Medicinal Chemistry, Oncology +14

Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines

Xiaohu Ouyang, Evgueni L. Piatnitski, Vatee Pattaropong et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 99 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors

Alessandro A. Boezio, Loren Berry, Brian K. Albrecht et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 56 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +13

Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors

Felix González-López de Turiso, Youngsook Shin, Matthew F. Brown et al. · Journal of Medicinal Chemistry · 2012 · 50 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of (<i>R</i>)-6-(1-(8-Fluoro-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6<i>H</i>)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity

Alessandro A. Boezio, Katrina W. Copeland, Karen Rex et al. · Journal of Medicinal Chemistry · 2016 · 35 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13